Fidelity Select Pharmaceuticals Portfolio Top holdings include Apple, Amazon, Google, and Facebook. The goal of this fund is to double the performance of the NASDAQ-100. This fund has a 16% average annual return since being founded in 2004, and a 50% annual return since the bottom in early 2009. Investors tough enough to endure a brutal 2008 will have seen this mutual fund rebound nicely. This is another fund that should probably come with a bottle of ulcer medication. Rydex Dynamic NASDAQ-100 2x Strategy Class A Anyone who invested $10,000 into this fund back in 2000 would have about $45,000 today. Investors should be especially pleased with the 64% return in the past year. This fund has been a solid performer for more than a decade, with an average annual return of more than 14% since the start of 2000, and more than 19% since 2005. Its holdings include some of the biggest names in biotech, including Gilead Sciences, Amgen, and Alexion Pharmaceuticals. It's recorded a 21% average annual return in the last decade and a 63% average annual return in the last three years. But that risk has paid off for investors with an average annual 9% return since being founded in June of 2000. It has high fees and a high minimum investment ($15,000), and uses leverage to maximize returns. ProFunds BioTechnology UltraSector Fund Investor Class Gilead, Amgen, and Celgene are the top holdings in this fund. It boasts a 17% average annual return over the last decade, and a more than 50% return over the last year. This fund would have netted $57,000 from a $10,000 investment at the start. Rydex Basic Biotechnology Fund Class A įounded in 2004, here's a fund that has ridden the wave of hot biotech stocks. Top holdings are Biomarin Pharmaceutical, Shire, and Allergan. A $10,000 investment at the start of 2000 would be worth more than $130,000 now. It's hard to complain about an 18% average annual return over the last 15 years. Prudential Jennison Health Sciences Fund Z Just remember that past performance does not guarantee future returns. Here's to hoping these funds can give your portfolio a boost. There are also other funds that have done exceptionally well in the last 10 years, but did not make the list because of bad performance between 20. It's worth noting that there are several funds that could be on this list, but are now closed to new investors. It is heavy on biotechnology and health funds, driven by some of the biggest gainers in the stock market over the last 15 years. This list was compiled using historical data on annual average returns from Morningstar and Fidelity. It's a particularly fun exercise to examine the funds that have performed best since the year 2000. If you're looking to supercharge your investment returns, it's often helpful to look at some of the best performing mutual funds of recent years.
0 kommentar(er)
